FSRH CEU Statement: Drospirenone Progestogen-onlyPill 1 FSRH CEU statement: Drospirenone 4mg progestogen-onlyPill (Slynd®) 10 Jan 2024 A new drospirenone progestogen-onlypill (DRSP POP) Slynd® is now available in the UK.1 CEU recommendations and guidance about DRSP POP can be found in the FSRH ProgestogenOnlyPills Guideline (2022)2. The following is a brief summary of key information. Pill guidance on missed pill management and requirement for emergency contraception when DRSP POP is used incorrectly can be found in the ‘ProgestogenOnlyPills’ Guideline FSRH ProgestogenOnlyPills Guideline .2 Contraceptive effectiveness Like the desogestrel POP, the DRSP POP acts primarily to suppress ovulation, with additional contraceptive effects on cervical mucus and endometrium.3 Studies3-5 indicate
Provision of the progestogen-onlypill by community pharmacies as bridging contraception for women receiving emergency contraception: the Bridge-it RCT Provision of the progestogen-onlypill by community pharmacies as bridging contraception for women receiving emergency contraception: the Bridge-it RCT * Text only * * Home * Journals * * Other NIHR research * * For authors * For reviewers
Giving the progestogenonlypill along with emergency contraception encouraged women to use long-term contraception NIHR Evidence - Giving the progestogenonlypill along with emergency contraception encouraged women to use long-term contraception - Informative and accessible health and care researchPharmacists gave the POP with emergency contraception - NIHR Evidence * * Evidence * About Us Sign UpWhat’s the issue?What’s new?Why is this important?What’s next?You may be interested to read Menu * Browse content * About Us * Glossary * Contact us * Site map * Cookies * Homepage * > * Giving the progestogenonlypill along with emerge...Giving the progestogenonlypill along with emergency contraception encouraged women to use long-term contraceptionHealth and Social Care Services
Interest in over-the-counter progestin-onlypills among transgender, nonbinary, and gender-expansive individuals in the United States. In July 2023, the US Food and Drug Administration approved the first non-prescription oral contraceptive, a progestin-onlypill, in the United States. Transgender, nonbinary, and gender-expansive people assigned female or intersex at birth face substantial contraceptive access barriers and may benefit from over-the-counter oral contraceptive access. However, no prior research has explored their perspectives on this topic. To measure interest in over-the-counter progestin-onlypill use among transgender, nonbinary, and gender-expansive individuals assigned female or intersex at birth. We conducted an online, cross-sectional survey from May-September 2019 (before
Evaluation of adherence to a daily progestin-onlypill in a simulated over-the-counter setting. The Adherence with Continuous Dose Oral Contraceptive: Evaluation of Self-Selection and Use (ACCESS) study assessed whether consumers can adhere to the regimen for a progestin-onlypill (norgestrel 0.075 mg) in an over-the-counter (OTC) setting. An actual use study in a simulated OTC environment
Effectiveness and efficacy rates of progestin-onlypills: A comprehensive literature review. To synthesize published literature on POP effectiveness and efficacy. We searched PubMed Central, PubMed, and the Cochrane library through March 07, 2022. We included articles written in English reporting a Pearl Index or life table rate for pregnancy. We excluded articles only assessing formulations
A commentary on progestin-onlypills and the "three-hour window" guidelines: Timing of ingestion and mechanisms of action. Clinical guidelines for progestin-onlypills (POPs) state that each pill should be taken at the same time each day, with only a "three-hour window" of tolerance before back-up contraception should be used. In this commentary, we summarize studies examining the timing
A review of the effectiveness of a progestogen-onlypill containing norgestrel 75 microg/day To review published data on the effectiveness of a progestogen-onlypill containing norgestrel 75 µg/day which should be under consideration by the FDA in 2022 for sale over the counter in the US. A literature search in MEDLINE, EMBASE, and COCHRANE REVIEWS using specified search terms and adding related
The effect of deliberate non-adherence to a norgestrel progestin-onlypill: a randomized, crossover study. To estimate the effects on cervical mucus, ovarian activity and theoretical contraceptive protection of a 6-hour delay and of missing one norgestrel 0.075 mg progestogen-onlypill (POP). In a prospective, two-site, randomized, crossover study, healthy women aged 18-35 with BMI <32.0 kg/m
Mechanism of action of norgestrel 0.075 mg a progestogen-onlypill. I. Effect on ovarian activity. To explore the effect on ovarian activity and ovulation of 28 days of correct daily use of a progestogen-onlypill containing norgestrel 0.075 mg. We performed a prospective, randomized, crossover study at 2 US sites, recruiting healthy women of reproductive age to use norgestrel 0.075 mg daily (follicle >13 mm diameter) without ovulation. Seventeen participants ovulated, of whom 12 (23.5%) had a normal, and 5 (9.8%) an abnormal luteal phase. Persistent ovarian follicles were common among women who had ovarian activity without ovulation, 17 of 26 participants (65.4%) had a large follicle which persisted beyond 28 days. During 28 days of exposure to a norgestrel 0.075 mg progestogen-onlypill
Mechanism of action of a 0.075 mg norgestrel progestogen-onlypill 2. Effect on cervical mucus and theoretical risk of conception. To evaluate the cervical mucus effects of a norgestrel 0.075 mg progestin-only contraceptive pill over a 28-day cycle. We recruited persons ages 18 to 35 with normal cycles at 2 US academic medical centers. Participants took norgestrel 0.075 mg daily for 28 days
Adherence among a cohort taking progestin-onlypills prescribed by a healthcare provider: Results of the BENCHMARK study. To measure adherence over six months of progestin-onlypill (POP) use. Prospective observational cohort study measuring adherence to daily dosing and timing of dose in patients prescribed a POP, with up to six months of follow-up, conducted from January to October 2020 and the same time of day, though the majority were not 100% adherent. This study reports data specific to adherence among those taking a progestin-onlypill (POP) in the prescription setting. Clinicians who counsel patients about POP use should be aware that majority of patients were not 100% adherent, although most report ≥85% adherence.
Modeling the Potential Benefit of an Over-the-Counter Progestin-OnlyPill in Preventing Unintended Pregnancies in the U.S. To develop a model to estimate the possible impact of use of an over-the-counter (OTC) progestin-onlypill (POP) on the number of unintended pregnancies in the US. Using typical use failure rates (7% for POPs), we compared the expected number of unintended pregnancies
Assessing the Pregnancy Protective Impact of Scheduled Nonadherence to a Novel Progestin-OnlyPill: Protocol for a Prospective, Multicenter, Randomized, Crossover Study. Progestin-only contraceptive pills (POP) are commonly reserved for women with medical comorbidities but in actuality, POPs can be safely used by anyone wanting to prevent pregnancy. This wide safety profile makes them an ideal
Use of effective contraception following provision of the progestogen-onlypill for women presenting to community pharmacies for emergency contraception (Bridge-It): a pragmatic cluster-randomised crossover trial. Unless women start effective contraception after oral emergency contraception, they remain at risk of unintended pregnancy. Most women in the UK obtain emergency contraception from community pharmacies. We hypothesised that pharmacist provision of the progestogen-onlypill as a bridging interim method of contraception with emergency contraception plus an invitation to a sexual and reproductive health clinic, in which all methods of contraception are available, would result in increased subsequent use of effective contraception. We did a pragmatic cluster-randomised crossover trial
Metabolic and laboratory effects of a progestin-onlypill containing drospirenone 4 mg in comparison to desogestrel 75 µg: a double-blind, double-dummy, prospective, randomised study. Steroid hormones in hormonal contraceptives influence a variety of metabolic parameters. Mainly, ethinyloestradiol (EE) in combined hormonal contraceptives (CHC) is a potent inducer of hepatic coagulation factors
Provision of the progestogen-onlypill by community pharmacies as bridging contraception for women receiving emergency contraception: the Bridge-it RCT. Unless women start effective contraception after using emergency contraception, they remain at risk of unintended pregnancy. Most women in the UK obtain emergency contraception from community pharmacies that are unable to provide ongoing contraception (apart from barrier methods which have high failure rates). This means that women need an appointment with a general practitioner or at a sexual and reproductive health clinic. We conducted a pragmatic cluster randomised cohort crossover trial to determine whether or not pharmacist provision of a bridging supply of a progestogen-onlypill plus the invitation to attend a sexual and reproductive
Progestin-onlypill use over 6 months postpartum. To determine progestin-onlypill (POP) use at 3 and 6 months postpartum among women who chose POPs at the postpartum visit. Secondary data analysis of a prospective observational study with telephone interviews at 3 and 6 months postpartum to assess contraceptive use. Of 440 women who attended the postpartum visit, 92 (20.9%) chose POPs. Current POP use was 44/84 (52.4%) at 3 months, 33/76 (43.4%) at 6 months, and 32/76 (42.1%) at both 3- and 6-month follow-up assessments. About half of women who plan POP use at the postpartum visit are not using this method at 3 months after delivery. About half of women with a prescription for progestin-onlypills will be not using this method at 3 months postpartum; further understanding of continued
A 1-year prospective, open-label, single-arm, multicenter, phase 3 trial of the contraceptive efficacy and safety of the oral progestin-onlypill drospirenone 4 mg using a 24/4-day regimen. To evaluate contraceptive effectiveness and safety of oral drospirenone 4 mg 24/4-day regimen in the United States. We performed a prospective, single-arm, multicenter phase 3 trial in sexually active women